



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/505,228	08/20/2004	Kenichiro Kataoka	Q83093	2360
23373	7590	10/25/2006	EXAMINER	
SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037			COLEMAN, BRENDA LIBBY	
			ART UNIT	PAPER NUMBER
			1624	

DATE MAILED: 10/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/505,228

Applicant(s)

KATAOKA ET AL.

Examiner

Brenda L. Coleman

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-49 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-49 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |                                                                                                            |                                                                                         |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                                           | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____.                                                |

### DETAILED ACTION

Claims 1-49 are pending in the application.

#### *Election/Restrictions*

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-8, 13-33 and 44-47, drawn to the compounds, compositions and method of use of the compounds of formula (I) where A is N, n is 1 and G<sup>0</sup> is CR<sup>1</sup>R<sup>2</sup> forming a pyrimido[4',5':4,5]pyrrolo[1,2-d][1,4]diazepine ring.

Group II, claim(s) 1, 34-39 and 44-47, drawn to the compounds, compositions and method of use of the compounds of formula (I) where A is C, n is 1 and G<sup>0</sup> is CR<sup>1</sup>R<sup>2</sup> forming a pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine.

Group III, claim(s) 1-8, 13-32 and 44-47, drawn to the compounds, compositions and method of use of the compounds of formula (I) where A is N, n is 0 and G<sup>0</sup> is CR<sup>1</sup>R<sup>2</sup> forming a pyrazino[1',2':1,5]pyrrolo[3,2-d]pyrimidine.

Group IV, claim(s) 1, 2, 9-11, 13-32, 40-42 and 44-47, drawn to the compounds, compositions and method of use of the compounds of formula (I) where A is N, n is 0 and G<sup>0</sup> is benzene forming a pyrimido[4',5':4,5]pyrrolo[1,2-d][1,4]benzodiazepine.

Group V, claim(s) 1-47, drawn to the compounds, compositions and method of use of the compounds of formula (I) not embraced by Groups I-IV above.

Group VI, claim(s) 48 and 49, drawn to the compounds of formula (II) where A is N, n is 1 and G<sup>0</sup> is CR<sup>1</sup>R<sup>2</sup> forming a pyrimido[4',5':4,5]pyrrolo[1,2-d][1,4]diazepine ring.

Group VII, claim(s) 48 and 49, drawn to the compounds of formula (II) where A is C, n is 1 and G<sup>0</sup> is CR<sup>1</sup>R<sup>2</sup> forming a pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine.

Group VIII, claim(s) 48 and 49, drawn to the compounds of formula (II) where A is N, n is 0 and G<sup>0</sup> is CR<sup>1</sup>R<sup>2</sup> forming a pyrazino[1',2':1,5]pyrrolo[3,2-d]pyrimidine.

Art Unit: 1624

Group IX, claim(s) 48 and 49, drawn to the compounds of formula (II) where A is N, n is 0 and G<sup>0</sup> is benzene forming a pyrimido[4',5':4,5]pyrrolo[1,2-d][1,4]benzodiazepine.

Group X, claim(s) 48 and 49, drawn to the compounds of formula (II) not embraced by Groups VI-IX above.

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I-IV and VI-IX are different significantly in chemical structures. They are consequently separately classified in the U.S. Patent Classification System and require separate searches in the Chemical literature. None of the prior art considers these groups as functional equivalents. Each group can support a patent. One does not require the other for their use. If, say, the pyrimido[4',5':4,5]pyrrolo[1,2-d][1,4]diazepine of Group I, were anticipated, applicants would not acquiesce in the objection of any of the Groups II-X there over or vice-versa and, thus, they are not linked to the same or corresponding special technical features.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

**Tentative election of a single species within the elected group is further required.**

If Groups V or X are elected further restriction may be required.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Art Unit: 1624

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00.

Art Unit: 1624

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Brenda L. Coleman  
Primary Examiner Art Unit 1624  
October 20, 2006